Benzinga | Jul 23, 2021 07:37AM EDT

Biofrontera To Sell Photodynamic Therapy For Skin Diseases In Poland Via Supply Pact With Medac

* Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ:BFRA) and Medac Gesellschaft f?r klinische Spezialpr?parate mbH have signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland.

* The agreement has a term of 5 years commencing with the start of sales in Poland.

* Under the terms of the agreement, Medac will make an immediate one-time upfront payment of (euro)50,000, plus an additional one-time payment of (euro)150,000 after the drug's reimbursement eligibility in Poland.

* In 2011, Ameluz was approved for photodynamic therapy (PDT) of mild to moderate actinic keratoses, field cancerization, and superficial and nodular basal cell carcinomas.

* Ameluz is approved for use in conventional PDT with red-light lamp BF-RhodoLED as well as for daylight PDT.

* Price Action: BFRA shares are up 1.7% at $6.55 during the premarket session on the last check Friday.